Results 41 to 50 of about 13,011 (272)

A Study of the Charge Transport Process at Nickel Hydroxide-Gold Modified Electrodes employing Rotating Disc Electrode Voltammetry and Ac Impedance Measurements [PDF]

, 2014
The aim of the present work was study how the charge-transport process of a nickel hydroxide film electrochemically synthesized on a gold substrate is modified when the electrode is stored without use for long time.
Tucceri, Ismael Ricardo
core   +3 more sources

Coordination chemistry and biology of chelators for the treatment of iron overload disorders [PDF]

, 2007
Treatment of the medical condition generally referred to as iron overload through the delivery of chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug deferasirox, which may be taken orally.
al-Refaie, al-Refaie, Allen, Anderegg, Armstrong, Atanasiu, Baker, Becker, Berdoukas, Bergeron, Bernhardt, Bernhardt, Bernhardt, Bernhardt, Brunner, Burkitt, Charalambous, Clarke, Dhungana, Dhungana, Dobbin, Donovan, Dragsten, Dunford, Fabio, Faller, Farrugia, Fischer, Ganguly, Ganz, Ghugre, Gyparaki, Ha, Hahn, Harris, Heinz, Henle, Hershko, Hershko, Hider, Hossain, Hossain, Kalinowski, Keberle, Kline, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Kontoghiorghes, Langemann, Lu, Maichle, Mathur, Merkofer, Naegeli, Nathan, Neufeld, Olivieri, Olivieri, Olivieri, Origa, Pang, Paul V. Bernhardt, Polomoscanik, Porter, Porter, Prelog, Raymond, Rice-Evans, Spasojevic, Steinhauser, Stumpf, Tam, Tam, Tripod, Van der Helm, Vichinsky, Wong, Wood   +81 more
core   +1 more source

Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report

BMC Nephrology, 2018
Background Although the renal toxicity of Deferasirox, an oral iron chelator, has been reported to be mild, there have been reports of acute interstitial nephritis or Fanconi syndrome due to this agent.
Keiko Oda, Kan Katayama, Akiko Tanoue, Tomohiro Murata, Yumi Hirota, Shoko Mizoguchi, Yosuke Hirabayashi, Takayasu Ito, Eiji Ishikawa, Kaoru Dohi, Masaaki Ito   +10 more
doaj   +1 more source

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience

Biology, 2022
Simple Summary Thalassemia is a hereditary anemia characterized by defect in hemoglobin synthesis. Patients with severe forms of the disease require regular blood transfusions, as well as iron chelation.
A. Adramerina, N. Printza, Emmanouel Hatzipantelis, Symeon Symeonidis, L. Tarazi, A. Teli, M. Economou   +6 more
semanticscholar   +1 more source

Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major [PDF]

, 2017
Chronic hepatitis C (CHC) significantly affects the prognosis of liver disease [1] and health related quality of life (HRQOL) in patients with β-thalassemia major [2, 3].
Biliotti, Elisa, Esvan, Rozenn, Franchi, Cristiana, Palazzo, Donatella, Serani, Marco, Silvestri, Alessandro M., Sorrentino, Francesco, Spaziante, Martina, Taliani, Gloria, Volpicelli, Lorenzo   +9 more
core   +1 more source

A speciation study on the perturbing effects of iron chelators on the homeostasis of essential metal ions [PDF]

, 2015
A number of reports have appeared in literature calling attention to the depletion of essential metal ions during chelation therapy on beta-thalassaemia patients. We present a speciation study to determine how the iron chelators used in therapy interfere
Alberti G, Biesuz R., Crespo Alonso M, CRISPONI, GUIDO, NURCHI, VALERIA MARINA, Sanna G, Zoroddu MA   +6 more
core   +6 more sources

Advances in iron chelation therapy: transitioning to a new oral formulation

Drugs in Context, 2017
Iron overload is a concern for patients who require repeated red-blood-cell transfusions due to conditions such as sickle cell disease, thalassemia, or myelodysplastic syndromes.
Nirmish R Shah
doaj   +1 more source

Deferasirox, an oral chelator in the treatment of iron overload

Italian Journal of Medicine, 2013
BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver,
I. Portioli
doaj   +1 more source

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Experimental Hematology & Oncology, 2020
Background Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging.
Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi, Giovan Battista Ruffo   +8 more
doaj   +1 more source

Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort

Haematologica, 2021
Transfusion-dependent patients typically develop iron-induced cardiomyopathy, liver disease, and endocrine complications. We aimed to estimate the incidence of endocrine disorders in transfusiondependent thalassemia (TDT) patients during long-term iron ...
M. Casale, G. Forni, E. Cassinerio, D. Pasquali, R. Origa, M. Serra, S. Campisi, A. Peluso, R. Renni, A. Cattoni, Elisa De Michele, Massimo Allò, M. Poggi, F. Ferrara, R. di Concilio, F. Sportelli, A. Quarta, M. Putti, L. Notarangelo, Antonella Sau, S. Ladogana, I. Tartaglione, S. Picariello, A. Marcon, Patrizia Sturiale, D. Roberti, A. I. Lazzarino, S. Perrotta   +27 more
semanticscholar   +1 more source